Back to Search
Start Over
Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a 'Treat-and-Extend' Regimen
- Source :
- Ophthalmology. Retina. 3(5)
- Publication Year :
- 2018
-
Abstract
- To report outcomes in patients with neovascular age-related macular degeneration (nAMD) after treatment with aflibercept for up to 4 years using a treat-and-extend (TE) regimen.Observational study.Patients with newly diagnosed nAMD treated with aflibercept in a TE protocol.Subjects received 3 injections of aflibercept at monthly intervals followed by a TE protocol for at least 12 months. At each clinical visit after the loading phase, OCT and best-corrected visual acuity (BCVA) testing were performed to monitor disease activity.Change in BCVA over time, number of injections and visits per year, and percentage of patients reaching a treatment interval of ≥12 weeks.Of 231 consecutive eyes (231 patients) with a mean follow-up time of 2.9 (1-5.5) years, 173 were followed up for ≥2 years, 112 were followed up for ≥3 years, and 62 were followed up for ≥4 years. Mean BCVA increased from 59.8 letters (20/60) at diagnosis to 65.8 letters (20/50) after the loading phase (+6.0 letters; standard deviation [SD], 11.1) and to 65.5 letters at 12 months (+5.7 letters; [SD], 17). After 4 years of treatment, mean BCVA was maintained insignificantly better than baseline (63.4 letters, +3.6 letters gain, SD, 20.6; P 0.05). To achieve this, a mean of 7.7 (±1.2) injections and 4.4 (±1.6) clinic visits in the first year and 4.4 (±1.9) injections and 4.3 (±1.3) clinical visits per year thereafter were required. By 2 years of follow-up, 46.9% of patients reached a treatment interval of ≥12 weeks.By using a TE regimen, patients with nAMD maintained stable visual function over 4 years in a real-world setting with a reasonable treatment burden.
- Subjects :
- Male
Pediatrics
medicine.medical_specialty
Visual acuity
genetic structures
Recombinant Fusion Proteins
Visual Acuity
Angiogenesis Inhibitors
Drug Administration Schedule
03 medical and health sciences
Macular Degeneration
0302 clinical medicine
Age related
Ophthalmology
medicine
Humans
In patient
030304 developmental biology
Aflibercept
Aged
Retrospective Studies
Aged, 80 and over
0303 health sciences
business.industry
Retrospective cohort study
Macular degeneration
Middle Aged
medicine.disease
Regimen
Receptors, Vascular Endothelial Growth Factor
Intravitreal Injections
030221 ophthalmology & optometry
Treat and extend regimen
Female
medicine.symptom
business
medicine.drug
Subjects
Details
- ISSN :
- 24686530
- Volume :
- 3
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Ophthalmology. Retina
- Accession number :
- edsair.doi.dedup.....9e6e0b9e131c9e56478a293109c70d7d